Spinal Muscular Atrophy Type I

Rare Diseases
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Leadiant Biosciences
Leadiant BiosciencesMD - Rockville
1 program
1
Valproic Acid and LevocarnitinePhase 1/21 trial
Active Trials
NCT00661453Completed40Est. Jun 2012
Novartis
NovartisBASEL, Switzerland
2 programs
In-home body weight support harness systemN/A1 trial
Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in SpainN/A1 trial
Active Trials
NCT05715749Completed33Est. Jul 2024
NCT06632730Completed69Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Leadiant BiosciencesValproic Acid and Levocarnitine
NovartisTherapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain
NovartisIn-home body weight support harness system

Clinical Trials (3)

Total enrollment: 142 patients across 3 trials

NCT00661453Leadiant BiosciencesValproic Acid and Levocarnitine

CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I

Start: Apr 2008Est. completion: Jun 201240 patients
Phase 1/2Completed
NCT06632730NovartisTherapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain

Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain

Start: Jul 2023Est. completion: Nov 202369 patients
N/ACompleted
NCT05715749NovartisIn-home body weight support harness system

Body Weight Support Harness System in Spinal Muscular Atrophy

Start: Sep 2018Est. completion: Jul 202433 patients
N/ACompleted

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space